The global fibromyalgia treatment market size accounted for USD 3.63 billion in 2025 and is forecasted to hit around USD 5.16 billion by 2034, representing a CAGR of 3.97% from 2025 to 2034. The North America market size was estimated at USD 1.88 billion in 2024 and is expanding at a CAGR of 4.10% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Fibromyalgia Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Fibromyalgia Treatment Market, by Treatment Type
8.1.1. Pharmacologic Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-Pharmacologic Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Device & Neuromodulation Therapies
8.1.3.1. Market Revenue and Forecast
8.1.4. Digital Therapeutics
8.1.4.1. Market Revenue and Forecast
8.1.5. Combination / Multimodal Care Pathways
8.1.5.1. Market Revenue and Forecast
9.1. Fibromyalgia Treatment Market, by Pharmacologic Class
9.1.1. Anticonvulsants / Α2δ Ligands
9.1.1.1. Market Revenue and Forecast
9.1.2. SNRIs
9.1.2.1. Market Revenue and Forecast
9.1.3. SNRIs
9.1.3.1. Market Revenue and Forecast
9.1.4. Opioids & Weak Opioids
9.1.4.1. Market Revenue and Forecast
9.1.5. Analgesics / NSAIDs
9.1.5.1. Market Revenue and Forecast
9.1.6. NMDA Modulators, Serotonergic Modulators, Novel Small Molecules
9.1.6.1. Market Revenue and Forecast
9.1.7. Cannabinoids & Complementary Botanicals
9.1.7.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type
10.1.2. Market Revenue and Forecast, by Pharmacologic Class
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type
10.1.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type
10.1.4.2. Market Revenue and Forecast, by Pharmacologic Class
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type
10.2.2. Market Revenue and Forecast, by Pharmacologic Class
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type
10.2.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type
10.2.4.2. Market Revenue and Forecast, by Pharmacologic Class
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type
10.2.5.2. Market Revenue and Forecast, by Pharmacologic Class
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type
10.2.6.2. Market Revenue and Forecast, by Pharmacologic Class
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type
10.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type
10.3.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type
10.3.4.2. Market Revenue and Forecast, by Pharmacologic Class
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type
10.3.5.2. Market Revenue and Forecast, by Pharmacologic Class
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type
10.3.6.2. Market Revenue and Forecast, by Pharmacologic Class
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type
10.4.2. Market Revenue and Forecast, by Pharmacologic Class
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type
10.4.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type
10.4.4.2. Market Revenue and Forecast, by Pharmacologic Class
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type
10.4.5.2. Market Revenue and Forecast, by Pharmacologic Class
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type
10.4.6.2. Market Revenue and Forecast, by Pharmacologic Class
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type
10.5.2. Market Revenue and Forecast, by Pharmacologic Class
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type
10.5.3.2. Market Revenue and Forecast, by Pharmacologic Class
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type
10.5.4.2. Market Revenue and Forecast, by Pharmacologic Class
11.1. Pfizer
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Eli Lilly
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Allergan / AbbVie
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Teva Pharmaceutical Industries
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Novartis
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sun Pharmaceutical Industries
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Astellas Pharma
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Tonix Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Aptinyx
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Axsome Therapeutics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description